CN114585607B - N-叔丁基-4[[2-(5-氯-2-羟基-苯基)乙酰基]氨基]吡啶-2-甲酰胺的固体形式 - Google Patents

N-叔丁基-4[[2-(5-氯-2-羟基-苯基)乙酰基]氨基]吡啶-2-甲酰胺的固体形式

Info

Publication number
CN114585607B
CN114585607B CN202080053826.8A CN202080053826A CN114585607B CN 114585607 B CN114585607 B CN 114585607B CN 202080053826 A CN202080053826 A CN 202080053826A CN 114585607 B CN114585607 B CN 114585607B
Authority
CN
China
Prior art keywords
compound
polymorph
degrees
solvent
type
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN202080053826.8A
Other languages
English (en)
Chinese (zh)
Other versions
CN114585607A (zh
Inventor
S·科林伍德
R·梅林
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
TMEM16A Ltd
Original Assignee
TMEM16A Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by TMEM16A Ltd filed Critical TMEM16A Ltd
Publication of CN114585607A publication Critical patent/CN114585607A/zh
Application granted granted Critical
Publication of CN114585607B publication Critical patent/CN114585607B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/81—Amides; Imides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
CN202080053826.8A 2019-07-25 2020-07-24 N-叔丁基-4[[2-(5-氯-2-羟基-苯基)乙酰基]氨基]吡啶-2-甲酰胺的固体形式 Active CN114585607B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB1910664.0A GB201910664D0 (en) 2019-07-25 2019-07-25 Novel forms of compound
GB1910664.0 2019-07-25
PCT/GB2020/051779 WO2021014167A1 (en) 2019-07-25 2020-07-24 Solid forms of n-tert-butyl-4[[2-(5-chloro-2-hydroxy-phneyl)acetyl]amino]pyridine-2-carboxamide

Publications (2)

Publication Number Publication Date
CN114585607A CN114585607A (zh) 2022-06-03
CN114585607B true CN114585607B (zh) 2025-11-14

Family

ID=67990591

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202080053826.8A Active CN114585607B (zh) 2019-07-25 2020-07-24 N-叔丁基-4[[2-(5-氯-2-羟基-苯基)乙酰基]氨基]吡啶-2-甲酰胺的固体形式

Country Status (19)

Country Link
US (1) US12281077B2 (https=)
EP (1) EP4003960A1 (https=)
JP (1) JP7627683B2 (https=)
KR (1) KR20220087430A (https=)
CN (1) CN114585607B (https=)
AU (1) AU2020318943A1 (https=)
BR (1) BR112022001276A2 (https=)
CA (1) CA3145285A1 (https=)
CL (1) CL2022000187A1 (https=)
CO (1) CO2022002046A2 (https=)
CR (2) CR20220079A (https=)
GB (1) GB201910664D0 (https=)
IL (1) IL290071B1 (https=)
MX (1) MX2022000891A (https=)
MY (1) MY207877A (https=)
PE (1) PE20221407A1 (https=)
PH (1) PH12022550193A1 (https=)
UA (1) UA129300C2 (https=)
WO (1) WO2021014167A1 (https=)

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111683926A (zh) * 2018-01-26 2020-09-18 企业治疗学有限公司 化合物

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050176767A1 (en) * 2003-10-30 2005-08-11 Laval Chan Chun Kong Pyridine carboxamide and methods for inhibiting HIV integrase
CA2658362A1 (en) 2006-06-29 2008-01-03 Alantos Pharmaceuticals Holding, Inc. Metalloprotease inhibitors
WO2016042114A1 (en) * 2014-09-19 2016-03-24 F. Hoffmann-La Roche Ag Cxcl14 as a biomarker of hedgehog pathway activity for the diagnosis, prognosis and treatment of idiopathic pulmonary fibrosis
US11358947B2 (en) 2017-04-17 2022-06-14 The Regents Of The University Of California Substituted 2-acylamino-cycloalkylthiophene-3-carboxylic acid arylamides as inhibitors of calcium-activated chloride channel TMEM16A

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111683926A (zh) * 2018-01-26 2020-09-18 企业治疗学有限公司 化合物

Also Published As

Publication number Publication date
CA3145285A1 (en) 2021-01-28
GB201910664D0 (en) 2019-09-11
IL290071B1 (en) 2026-02-01
AU2020318943A1 (en) 2022-03-17
JP2022542918A (ja) 2022-10-07
BR112022001276A2 (pt) 2022-03-22
JP7627683B2 (ja) 2025-02-06
KR20220087430A (ko) 2022-06-24
PH12022550193A1 (en) 2023-01-09
MX2022000891A (es) 2022-05-26
EP4003960A1 (en) 2022-06-01
US20220220074A1 (en) 2022-07-14
US12281077B2 (en) 2025-04-22
CL2022000187A1 (es) 2022-10-07
CO2022002046A2 (es) 2022-06-10
CR20220079A (es) 2022-06-28
CR20250316A (es) 2025-08-27
UA129300C2 (uk) 2025-03-12
CN114585607A (zh) 2022-06-03
IL290071A (en) 2022-03-01
WO2021014167A1 (en) 2021-01-28
PE20221407A1 (es) 2022-09-20
MY207877A (en) 2025-03-25

Similar Documents

Publication Publication Date Title
CN111683926B (zh) 化合物
US7960551B2 (en) Compound
EP3794002B1 (en) Compounds
EP3490978B1 (en) Salts of 2, 6-dimethylpyrimidone derivatives and uses thereof
EP3697788B1 (en) Bis(pentahydroxyhexyl)amino substituted 2-{[(3-amino-pyrazin-2-yl)formamido]methyl}-1h-1,3-benzodiazol-3-ium derivatives as enac inhibitors for treating respiratory diseases
CN114585607B (zh) N-叔丁基-4[[2-(5-氯-2-羟基-苯基)乙酰基]氨基]吡啶-2-甲酰胺的固体形式
CN114269721B (zh) 用于治疗呼吸系统疾病的化合物
RU2843949C2 (ru) Твердые формы n-трет-бутил-4[[2-(5-хлор-2-гидроксифенил)ацетил]амино]пиридин-2-карбоксамида
WO2020249956A9 (en) Modulators of tmem16a for treating respiratory disease
HK40068903A (en) Solid forms of n-tert-butyl-4[[2-(5-chloro-2-hydroxy-phneyl)acetyl]amino]pyridine-2-carboxamide
WO2021014168A1 (en) Solid forms of 4-[[2-(5-chloro-2-hydroxy-phenyl)acetyl]amino]-n-(1,1-dimethylprop-2-ynyl)pyridine-2-carboxamide
CN105384730A (zh) 依帕列净的晶型及其制备方法、药物组合物和用途
US20130012479A1 (en) Polymorphs of 6-(piperidin-4-yloxy)-2h-isoquinolin-1-one hydrochloride
KR102836470B1 (ko) 3-{[5-(아제티딘-1-일카르보닐)피라진-2-일]옥시}-5-{[(1s)-1-메틸-2-(메틸옥시)에틸]옥시)-n-(5-메틸피라진-2-일)벤즈아미드의치료 공결정
WO2021014169A1 (en) Crystalline form of 4-[[2-(5-chloro-2-hydroxy-phenyl)acetyl]amino]-n-cyclohexyl-pyridine-2-carboxamide
EP2729460B1 (en) Crystalline solvates of 6-(piperidin-4-yloxy)-2h-isoquinolin-1-one hydrochloride
CN114929683B (zh) 作为钙激活氯化物通道调节剂的吡啶衍生物
CN116745267A (zh) 用于治疗呼吸系统疾病的苯并咪唑衍生物
HK40067765B (zh) 用於治疗呼吸系统疾病的tmem16a的调节剂
HK40100262A (zh) 用於治疗呼吸系统疾病的苯并咪唑衍生物
HK40009059A (en) Salts of 2, 6-dimethylpyrimidone derivatives and uses thereof
HK40009059B (en) Salts of 2, 6-dimethylpyrimidone derivatives and uses thereof
HK1192546B (en) Crystalline solvates of 6-(piperidin-4-yloxy)-2h-isoquinolin-1-one hydrochloride

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40068903

Country of ref document: HK

GR01 Patent grant
GR01 Patent grant